$SCNIAug 24, 2026, 7:01 AM ETAI processed
SCNI H1 2026: CDMO momentum — $3.1M committed orders, expanded U.S. clinical manufacturing program
AI Summary
Scinai (SCNI) reported H1 2026 results showing revenues of $0.95M and a gross loss of ~$2.4M with operating loss of ~$4.6M; net income of ~$1.6M was driven by a non-cash $6.4M bargain purchase gain from its Recipharm Israel acquisition, while cash used in operations was ~$3.9M and cash on hand totaled ~$2.9M. The company highlighted CDMO momentum: committed customer orders of ~$3.1M (≈$2.1M invoiced) as of Aug. 16, an expanded U.S. clinical manufacturing and CMC program (≈$650k in advances received) intended to support a planned U.S. IND and Phase III work, and a target of roughly $5M CDMO revenue for 2026 while definitive commercial terms remain under negotiation.
Positives
- Committed customer orders of approximately $3.1M as of Aug 16, 2026 (≈$2.1M invoiced)
- Expanded U.S. clinical manufacturing/CMC program underway with ~$650k in cash payments/advances received
- Acquisition of Recipharm Israel produced a $6.4M bargain purchase gain and added cash/assets supporting liquidity
Negatives
- H1 revenue modest at $949k with a gross loss of ~$2.4M and operating loss of ~$4.6M
- Cost of revenues rose to $3.3M reflecting higher CDMO operating costs while facility utilization is still ramping
- Expanded U.S. program’s definitive agreement is still being negotiated, so future revenue is not yet guaranteed